Clinical Trial Update: Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse [Phase 4]

View source ↗

Summary

Clinical trial update on lumateperone as adjunctive therapy for major depressive disorder in patients with early life trauma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Caplyta (lumateperone)

Snippet

Sponsor: University of Texas at Austin | Conditions: Major Depressive Diorder, Early Life Trauma | Phase 4 | Status: NOT_YET_RECRUITING